|
Not too long ago, R&D pipeline failures would be attributed to the new products not being effective, safe, or reliable, which may have led to an inability to secure regulatory approval. But with the changing healthcare economic climate, new products must show “evidence” that they reduce healthcare costs and improve patient outcomes in order to gain payer approval and ultimately market access.
Navigating a new product through this new and uncertain reimbursement environment is possible only if the new requirements are incorporated early in the development plan. Our panel of industry experts will offer their practical advice on approaches, tools and techniques for product development planning that takes into account payer, provider and patient evidence requirements. This topic applies to start-up firms, and to large companies alike. Schedule of Events: 11:30-12:00 pm registration and networking 12:00-12:30 pm lunch 12:30-12:40 pm opening remarks 12:40-1:00 pm topic overview presentation 1:00-2:30 am panel discussion and audience Q&A
Moderator:
Andy Myslicki, Operations Director, Integrated Project Management Co
Speakers:
Dr. Omar Dabbous, Head of QSci and Payer Evidence Group, GSK Liam Farrell, Director, Medical Affairs Program Management, Astellas Pharma USA Garry Pinter, Senior Director Project Management, AbbVie
Eric Henning, Global Program Leader, Therapeutic Area Management & Operations, Takeda Pharmaceuticals International, Inc.
|
Print Page